A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

To generate chimeric Ag receptors (CARs) for the adoptive immunotherapy of cancer patients with ErbB2-expressing tumors, a single-chain Ab derived from the humanized mAb 4D5 Herceptin (trastuzumab) was initially linked to T cell signaling domains derived from CD28 and the CD3ζ to generate a CAR agai...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunol
Autori principali: Zhao, Yangbing, Wang, Qiong J., Yang, Shicheng, Kochenderfer, James N., Zheng, Zhili, Zhong, Xiaosong, Sadelain, Michel, Eshhar, Zelig, Rosenberg, Steven A., Morgan, Richard A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6292203/
https://ncbi.nlm.nih.gov/pubmed/19843940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.0900447
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi